Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261592 | 0.97 | — | — | |
| SCHEMBL12244538 | 0.97 | — | — | |
| SCHEMBL12529886 | 0.92 | — | — | |
| Piperidine SCHEMBL9404500 | 0.87 | ALDH1A1 (0.38) | MAPTATMMEN1KMT2AFDPS | |
| SCHEMBL11500196 | 0.85 | MAPT (0.42) | MAPTATMMEN1KMT2A | |
| SCHEMBL10451647 | 0.79 | MEN1 (0.37) | MAPTATMMEN1KMT2AFDPS | |
| SCHEMBL1744094 | 0.76 | MEN1 (0.39) | MAPTATMMEN1KMT2AFDPS | |
| SCHEMBL31298228 | 0.76 | MEN1 (0.39) | MAPTATMMEN1KMT2AFDPS | |
| SCHEMBL81243 | 0.76 | MEN1 (0.39) | MAPTATMMEN1KMT2AFDPS | |
| SCHEMBL27854795 | 0.76 | MEN1 (0.39) | MAPTATMMEN1KMT2AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIV STRASBOURG (FR) | 2017-06-22 | — | — | US | disclosed |
| WO-2012022837-A1 | TRANSDERMAL COMPOSITIONS | HELSINGIN YLIOPISTO (FI) | 2012-02-23 | — | — | WO | disclosed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
| EP-0644885-A1 | NOVEL BIOLOGICALLY ACTIVE EBURNAMENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHETER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025550-A1 | NOVEL BIOLOGICALLY ACTIVE EBURNAMENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHETER GEDEON VEGYÉSZETI GYÁR RT. (HU) | 1993-12-23 | — | — | WO | disclosed |
| EP-0151702-B1 | ALPHA-HYDROXYKETONE ACETALS | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1987-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | MAPT 1022/4885ATM 137/4885MEN1 4532/4885 |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | MAPT 2670/4885ATM 817/4885MEN1 1709/4885 |
| US-20090253681-A1 | HIV Integrase Inhibitors | REV1, INTS9, H1-10 | MAPT 3157/4885ATM 1352/4885MEN1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.